Tarlatamab-Imdelltra official instructions and instructions for use

Tarlatamab (trade name: Imdelltra) is a new bispecific T-cell engager (BiTE) that is mainly used to treat specific types of solid tumors. The drug activates the patient's own T cells to kill tumor cells by connecting specific antigens on the surface of tumor cells with CD3 receptors on T cells, thereby enhancing the immune system's ability to target tumors. This mechanism of action makes talatumumab show potential therapeutic value in patients for whom traditional chemotherapy and monoclonal antibody treatments have limited efficacy.

According to the official instructions, the indications for talatumumab are mainly for patients with advanced or metastatic solid tumors, especially those who have been ineffective or resistant to standard therapies. In clinical trials, the drug is administered through intravenous drip, and the dosage and dosage regimen are individually adjusted by doctors based on the patient's weight, tumor type, and immune status. Usually the initial dose is lower to observe patient tolerance and titrated to the recommended dose to maximize efficacy while reducing the risk of side effects. During the infusion process, vital signs such as blood pressure, heart rate, and body temperature need to be closely monitored to prevent acute immune-related reactions.

In terms of safety, common adverse reactions of talatumumab include cytokine release syndrome (CRS), fever, fatigue, nausea and hematological abnormalities. Cytokine release syndrome is a typical reaction to BiTE drugs, manifesting as fever, chills, hypotension, difficulty breathing and other symptoms, which may be life-threatening in severe cases. Therefore, it is clinically recommended to be hospitalized or in an environment with emergency conditions during the first administration and dose adjustment period, and use glucocorticoid or anti-IL-6 therapeutic intervention if necessary. In addition, some patients may experience lymphopenia, decreased platelets, or abnormal liver function indicators, and require regular monitoring of blood routine and liver and kidney functions.
The guidelines for use emphasize that talatumumab needs to be administered and administered by experienced doctors in professional medical institutions. During treatment, tumor response and immune-related indicators should be regularly evaluated, and the dose should be adjusted or the dosing interval extended according to the patient's clinical condition. At the same time, patients and their families should be informed of the necessary information about potential side effects, symptom identification, and emergency medical treatment to ensure a safe and reliable treatment process. In areas where the drug is not on the market, patients can obtain it through clinical trials or special medication channels, but strict approval and regulatory procedures must be followed.
Overall, talatumumab, as a new generation of bispecific T-cell activating antibodies, provides a new treatment option for patients with advanced tumors. By activating the autoimmune system to target and kill tumor cells, significant therapeutic effects can be achieved in patients for whom traditional therapies have limited efficacy. However, its treatment process requires high drug safety, and it needs to follow official instructions and usage guidelines, as well as strict monitoring and supportive treatment. Through scientific and standardized application, talatumumab is expected to play an important role in future tumor immunotherapy and improve patient survival rate and quality of life.
Reference: https://www.drugs.com/